This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/4/2026
Thank you for standing by and welcome to the Cytokinetics Q3 2026 earnings call. This call is being recorded and all participants are in a listen-only mode. After the speaker's remarks, we will open the call to questions. We will allow for one question per participant. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star 1 again. I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Affairs. Please go ahead.
Good afternoon and thanks for joining us on the call today. The slides accompanying today's webcast can be found on the Investors and Media section of our website at cytokinetics.com along with today's press release. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Andrew Callos, EVP and Chief Commercial Officer, will discuss the commercial launch of myCORSO in the U.S. and Europe. Fady Malik, EVP of R&D, will provide updates related to Abdi Kampson. Steve Heitner, SVP and Chief Medical Officer, will provide updates related to our ongoing clinical development programs. Sung Lee, EVP and Chief Financial Officer, will provide a financial overview for the quarter, and finally, Robert will make closing remarks. As you can see on this slide, today's discussion will include forward-looking statements which are subject to risks and uncertainties. Please refer to our SEC filings for a discussion of these factors. And now, I will turn the call over to Robert.
Thank you, Diane, and thanks to all for joining us on the call today. The third quarter was another period of strong execution for cytokinetics, Thank you for joining us. The number of prescribers, prescribing per physician, and patients dispensed all increased. We believe these trends reflect the differentiated profile of mycorrhizal and we see significant room for continued growth. Outside the United States, our launch in Germany is off to a strong start and we continue to secure approvals in additional geographies, including recently in Canada and the United Kingdom. We expect to launch in the UK this quarter and in additional countries in 2027. We're also looking forward to the PDUFA date for data relating to Maple HCM, which is November 14th. Beyond OHCM, we're working diligently to bring Avicampton to more patients living with HCM. In August, we presented the full results from Acacia HCM Thank you for joining us. from pre-specified analyses from Acacia HCM that further underscore the potential of afecampton in N-HCM. These results bring us closer to the potential commercial availability of a treatment for the full spectrum of symptomatic HCM patients. Based on these results, we're on track to submit a supplemental NDA to FDA this quarter and an application to the EMA in early 2027. At the same time, pending regulatory approval, we're preparing for the potential launch in NHCM, building on the commercial foundation we've established with myCORSO in OHCM. Andrew will share more on our commercial readiness in a moment. And beyond Afficampton, we continue to advance our pipeline during the quarter. Our third quarter results demonstrate the progress we're making towards our vision 2030. Looking ahead, our third quarter results demonstrate the progress we're making towards our vision 2030. Our priorities are clear. Submit the SMDA in NHCM, prepare for a potential NHCM launch, expand my Corso into additional geographies, and importantly, continue our commercial momentum in OHCM while advancing our pipeline, all while staying disciplined to how we deploy capital. And with that, I'll now turn the call over to Andrew, please.
You're reading a preview of the CYTK Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing